181 related articles for article (PubMed ID: 36345507)
1. HA-DOPE-Modified Honokiol-Loaded Liposomes Targeted Therapy for Osteosarcoma.
Zhang X; Chen H; Zhang Y; Huang Q; Feng J; Xing H; Fu X; Yan X; Zhang Y; Xu Q; Liang J
Int J Nanomedicine; 2022; 17():5137-5151. PubMed ID: 36345507
[TBL] [Abstract][Full Text] [Related]
2. Hyaluronic acid-modified liposomal honokiol nanocarrier: Enhance anti-metastasis and antitumor efficacy against breast cancer.
Wang J; Liu D; Guan S; Zhu W; Fan L; Zhang Q; Cai D
Carbohydr Polym; 2020 May; 235():115981. PubMed ID: 32122511
[TBL] [Abstract][Full Text] [Related]
3. Engineering of Bone- and CD44-Dual-Targeting Redox-Sensitive Liposomes for the Treatment of Orthotopic Osteosarcoma.
Feng S; Wu ZX; Zhao Z; Liu J; Sun K; Guo C; Wang H; Wu Z
ACS Appl Mater Interfaces; 2019 Feb; 11(7):7357-7368. PubMed ID: 30682240
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamic evaluation of hyaluronic acid-modified imatinib-loaded PEGylated liposomes in CD44-positive Gist882 tumor-bearing mice.
Huang J; Chen J
J Liposome Res; 2024 Mar; 34(1):97-112. PubMed ID: 37401372
[TBL] [Abstract][Full Text] [Related]
5. Redox-sensitive and hyaluronic acid functionalized liposomes for cytoplasmic drug delivery to osteosarcoma in animal models.
Chi Y; Yin X; Sun K; Feng S; Liu J; Chen D; Guo C; Wu Z
J Control Release; 2017 Sep; 261():113-125. PubMed ID: 28666726
[TBL] [Abstract][Full Text] [Related]
6. A novel honokiol liposome: formulation, pharmacokinetics, and antitumor studies.
Zhou C; Guo C; Li W; Zhao J; Yang Q; Tan T; Wan Z; Dong J; Song X; Gong T
Drug Dev Ind Pharm; 2018 Dec; 44(12):2005-2012. PubMed ID: 30058387
[TBL] [Abstract][Full Text] [Related]
7. Targeted delivery of honokiol by zein/hyaluronic acid core-shell nanoparticles to suppress breast cancer growth and metastasis.
Zhang Q; Wang J; Liu D; Zhu W; Guan S; Fan L; Cai D
Carbohydr Polym; 2020 Jul; 240():116325. PubMed ID: 32475585
[TBL] [Abstract][Full Text] [Related]
8. Hyaluronic acid-modified DOTAP/DOPE liposomes for the targeted delivery of anti-telomerase siRNA to CD44-expressing lung cancer cells.
Taetz S; Bochot A; Surace C; Arpicco S; Renoir JM; Schaefer UF; Marsaud V; Kerdine-Roemer S; Lehr CM; Fattal E
Oligonucleotides; 2009 Jun; 19(2):103-16. PubMed ID: 19374532
[TBL] [Abstract][Full Text] [Related]
9. Honokiol suppresses proliferation and induces apoptosis via regulation of the miR‑21/PTEN/PI3K/AKT signaling pathway in human osteosarcoma cells.
Yang J; Zou Y; Jiang D
Int J Mol Med; 2018 Apr; 41(4):1845-1854. PubMed ID: 29393336
[TBL] [Abstract][Full Text] [Related]
10. Polysialic acid-functionalized liposomes for efficient honokiol delivery to inhibit breast cancer growth and metastasis.
Li X; Guan S; Li H; Li D; Liu D; Wang J; Zhu W; Xing G; Yue L; Cai D; Zhang Q
Drug Deliv; 2023 Dec; 30(1):2181746. PubMed ID: 36803115
[TBL] [Abstract][Full Text] [Related]
11. Resveratrol Loaded by Folate-Modified Liposomes Inhibits Osteosarcoma Growth and Lung Metastasis via Regulating JAK2/STAT3 Pathway.
Zhu WT; Zeng XF; Yang H; Jia ML; Zhang W; Liu W; Liu SY
Int J Nanomedicine; 2023; 18():2677-2691. PubMed ID: 37228445
[TBL] [Abstract][Full Text] [Related]
12. Reduction-sensitive CD44 receptor-targeted hyaluronic acid derivative micelles for doxorubicin delivery.
Yang Y; Zhao Y; Lan J; Kang Y; Zhang T; Ding Y; Zhang X; Lu L
Int J Nanomedicine; 2018; 13():4361-4378. PubMed ID: 30100720
[TBL] [Abstract][Full Text] [Related]
13. Hyaluronic acid modified daunorubicin plus honokiol cationic liposomes for the treatment of breast cancer along with the elimination vasculogenic mimicry channels.
Ju RJ; Cheng L; Qiu X; Liu S; Song XL; Peng XM; Wang T; Li CQ; Li XT
J Drug Target; 2018 Nov; 26(9):793-805. PubMed ID: 29334266
[TBL] [Abstract][Full Text] [Related]
14. Multifunctional tumor-targeting nanocarriers based on hyaluronic acid-mediated and pH-sensitive properties for efficient delivery of docetaxel.
Song S; Chen F; Qi H; Li F; Xin T; Xu J; Ye T; Sheng N; Yang X; Pan W
Pharm Res; 2014 Apr; 31(4):1032-45. PubMed ID: 24154802
[TBL] [Abstract][Full Text] [Related]
15. Hyaluronic acid-bearing lipoplexes: physico-chemical characterization and in vitro targeting of the CD44 receptor.
Dufaÿ Wojcicki A; Hillaireau H; Nascimento TL; Arpicco S; Taverna M; Ribes S; Bourge M; Nicolas V; Bochot A; Vauthier C; Tsapis N; Fattal E
J Control Release; 2012 Sep; 162(3):545-52. PubMed ID: 22820451
[TBL] [Abstract][Full Text] [Related]
16. Hybrid Cell Membrane-Functionalized Biomimetic Nanoparticles for Targeted Therapy of Osteosarcoma.
Cai JX; Liu JH; Wu JY; Li YJ; Qiu XH; Xu WJ; Xu P; Xiang DX
Int J Nanomedicine; 2022; 17():837-854. PubMed ID: 35228800
[TBL] [Abstract][Full Text] [Related]
17. Preparation and Quality Evaluation of Honokiol Nanoparticles Using a New Polysaccharide Polymer as its Carrier.
Weng Y; Zhang H; Xu S; Zhao Y; Ma L; Shi J; Qian K; Liang W; Xiong Y
Curr Drug Deliv; 2023; 20(2):183-191. PubMed ID: 35674293
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of growth and metastasis of breast cancer by targeted delivery of 17-hydroxy-jolkinolide B via hyaluronic acid-coated liposomes.
Liu D; Zhang Q; Wang J; Guan S; Cai D; Liu J
Carbohydr Polym; 2021 Apr; 257():117572. PubMed ID: 33541631
[TBL] [Abstract][Full Text] [Related]
19. Hyaluronic acid modified pH-sensitive liposomes for targeted intracellular delivery of doxorubicin.
Paliwal SR; Paliwal R; Agrawal GP; Vyas SP
J Liposome Res; 2016 Dec; 26(4):276-87. PubMed ID: 26784587
[TBL] [Abstract][Full Text] [Related]
20. Phytosterol-loaded CD44 receptor-targeted PEGylated nano-hybrid phyto-liposomes for synergistic chemotherapy.
Gautam M; Thapa RK; Gupta B; Soe ZC; Ou W; Poudel K; Jin SG; Choi HG; Yong CS; Kim JO
Expert Opin Drug Deliv; 2020 Mar; 17(3):423-434. PubMed ID: 32028805
[No Abstract] [Full Text] [Related]
[Next] [New Search]
